Divergent synthesis and identification of the cellular targets of deoxyelephantopins

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lagoutte, Roman ^a   Serba, Christelle ^a   Abegg, Daniel ^a   Hoch, Dominic G ^a   Adibekian, Alexander ^a   Winssinger, Nicolas ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYNE; CYSTEINE; DEOXYELEPHANTOPIN DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SESQUITERPENE LACTONE DERIVATIVE; STAUROSPORINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYELEPHANTOPIN; LACTONE; RECOMBINANT PROTEIN; SESQUITERPENE; ZINC FINGER PROTEIN;

BIOTECHNOLOGY; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; MEDICINE; METABOLITE; ORGANIC COMPOUND; PLANT EXTRACT; PROTEIN; PROTEOMICS; TRADITIONAL MEDICINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PROTEOMICS; ZINC FINGER MOTIF; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECT; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE; HUMANS; LACTONES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PPAR GAMMA; PROTEOMICS; RECOMBINANT PROTEINS; SESQUITERPENES; ZINC FINGERS;

EID: 84983348084     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12470     Document Type: Article

References (60)

1. Li, J. W. H. & Vederas, J. C. Drug discovery and natural products: end of an era or an endless frontier? Science 325, 161-165 (2009).
2. Newman, D. J. & Cragg, G. M. Natural Products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311-335 (2012).
3. Drahl, C., Cravatt, B. F. & Sorensen, E. J. Protein-reactive natural products. Angew. Chem. Int. Ed. 44, 5788-5809 (2005).
4. Robertson, J. G. Mechanistic basis of enzyme-targeted drugs. Biochemistry 44, 5561-5571 (2005).
5. Swinney, D. C. The role of binding kinetics in therapeutically useful drug action. Curr. Opin. Drug Discov. 12, 31-39 (2009).
6. Potashman, M. H. & Duggan, M. E. Covalent modifiers: an orthogonal approach to drug design. J. Med. Chem. 52, 1231-1246 (2009).
7. Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307-317 (2011).
8. Sanderson, K. Irreversible kinase inhibitors gain traction. Nat. Rev. Drug Discov. 12, 649-651 (2013).
9. Wender, P. A. & Miller, B. L. Synthesis at the molecular frontier. Nature 460, 197-201 (2009).
10. Schreiber, S. L. Organic chemistry: Molecular diversity by design. Nature 457, 153-154 (2009).
11. Shaw, J. T. Naturally diverse: highlights in versatile synthetic methods enabling target- and diversity-oriented synthesis. Nat. Prod. Rep. 26, 11-26 (2009).
12. Galloway, W. R., Isidro-Llobet, A. & Spring, D. R. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat. Commun. 1, 80-86 (2010).
13. Wetzel, S., Bon, R. S., Kumar, K. & Waldmann, H. Biology-oriented synthesis. Angew. Chem. Int. Ed. 50, 10800-10826 (2011).
14. Merfort, I. Perspectives on sesquiterpene lactones in inflammation and cancer. Curr. Drug Targets 12, 1560-1573 (2011).
15. Chadwick, M., Trewin, H., Gawthrop, F. & Wagstaff, C. Sesquiterpenoids Lactones: Benefits to Plants and People. Int. J. Mol. Sci. 14, 12780-12805 (2013).
16. Hoffmann, H. M. R. & Rabe, J. Synthesis and biological-activity of alphamethylene- gamma-butyrolactones. Angew. Chem. Int. Ed. 24, 94-110 (1985).
17. Kitson, R. R. A., Millemaggi, A. & Taylor, R. J. K. The renaissance of alphamethylene- gamma-butyrolactones: new synthetic approaches. Angew. Chem. Int. Ed. 48, 9426-9451 (2009).
18. Gersch, M., Kreuzer, J. & Sieber, S. A. Electrophilic natural products and their biological targets. Nat. Prod. Rep. 29, 659-682 (2012).
19. Lyss, G., Knorre, A., Schmidt, T. J., Pahl, H. L. & Merfort, I. The antiinflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappa B by directly targeting p65. J. Biol. Chem. 273, 33508-33516 (1998).
20. Lytton, J., Westlin, M. & Hanley, M. R. Thapsigarin inhibits the SERCA family of Ca-pump. J. Biol. Chem. 266, 17067-17071 (1991).
21. Shaikenov, T. E. et al. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase. Oncol. Rep. 8, 173-179 (2001).
22. Kunzmann, M. H., Bach, N. C., Bauer, B. & Sieber, S. A. alpha-Methylenegamma- butyrolactones attenuate Staphylococcus aureus virulence by inhibition of transcriptional regulation. Chem. Sci 5, 1158-1167 (2014).
23. Su, M., Wu, X., Chung, H. Y., Li, Y. & Ye, W. Antiproliferative activities of five chinese medicinal herbs and active compounds in Elephantopus scaber. Nat. Prod. Commun. 4, 1025-1030 (2009).
24. Huang, C.-C., Lo, C.-P., Chiu, C.-Y. & Shyur, L.-F. Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice. Br. J. Pharmacol. 159, 856-871 (2010).
25. Ichikawa, H. et al. Isodeoxyelephantopin, a novel sesquiterpene lactone, potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis through suppression of nuclear factor-kappa B (NF-kappa B) activation and NF-kappa B-regulated gene expression. Clin. Cancer Res. 12, 5910-5918 (2006).
26. Lee, W.-L., Wen, T.-N., Shiau, J.-Y. & Shyur, L.-F. Differential proteomic profiling identifies novel molecular targets of paclitaxel and phytoagent deoxyelephantopin against mammary Adenocarcinoma cells. J. Proteome Res. 9, 237-253 (2010).
27. Zou, G. et al. Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPAR gamma. Biochem. Pharmacol. 75, 1381-1392 (2008).
28. Zhang, F. H., Yang, Y. X., Xie, L. G. & Xu, X. H. Pd-catalyzed diastereoselective allylation of aldehydes with 3-bromomethyl-5H-furan-2-one: stereoselective synthesis of beta-(hydroxymethylaryl/alkyl)-alpha-methylenec-gammabutyrolactones with a syn configuration. Chem. Commun. 49, 4697-4699 (2013).
29. Hodgson, D. M., Talbot, E. P. A. & Clark, B. P. Stereoselective synthesis of beta-(Hydroxymethylaryl/alkyl)-alpha-methylene-gamma-butyrolactones. Org. Lett. 13, 2594-2597 (2011).
30. Furstner, A. & Muller, T. The first synthesis of a 10-membered ring by olefin metathesis: Jasmine ketolactone. Synlett 1997, 1010-1012 (1997).
31. Semmelhack, M. F. & Brickner, S. J. Intramolecular carbonylation of vinyl halides. J. Org. Chem. 46, 1723-1726 (1981).
32. Funk, T. W., Berlin, J. M. & Grubbs, R. H. Highly active chiral ruthenium catalysts for asymmetric ring-closing olefin metathesis. J. Am. Chem. Soc. 128, 1840-1846 (2006).
33. Fournier, P. A. et al. Mechanistically inspired catalysts for enantioselective desymmetrizations by olefin metathesis. Chem. Eur. J 14, 8690-8695 (2008).
34. Kress, S. & Blechert, S. Asymmetric catalysts for stereocontrolled olefin metathesis reactions. Chem. Soc. Rev. 41, 4389-4408 (2012).
35. Frantz, D. E., Fassler, R. & Carreira, E. M. Facile enantioselective synthesis of propargylic alcohols by direct addition of terminal alkynes to aldehydes. J. Am. Chem. Soc. 122, 1806-1807 (2000).
36. Fournier, J., Arseniyadis, S. & Cossy, J. A modular and scalable one-pot synthesis of polysubstituted furans. Angew. Chem. Int. Ed. 51, 7562-7566 (2012).
37. Fournier, J., Lozano, O., Menozzi, C., Arseniyadis, S. & Cossy, J. Palladiumcatalyzed asymmetric allylic alkylation of cyclic dienol carbonates: efficient route to enantioenriched gamma-butenolides bearing an all-carbon alphaquaternary stereogenic center. Angew. Chem. Int. Ed. 52, 1257-1261 (2013).
38. Trost, B. M., Xu, J. Y. & Schmidt, T. Palladium-catalyzed decarboxylative asymmetric allylic alkylation of enol carbonates. J. Am. Chem. Soc. 131, 18343-18357 (2009).
39. Fujioka, H. et al. Unexpected highly chemoselective deprotection of the acetals from aldehydes and not ketones: TESOTf-2, 6-lutidine combination. J. Am. Chem. Soc. 126, 11800-11801 (2004).
40. Stichnoth, D. et al. Photochemical formation of intricarene. Nat. Commun. 5, 5597 (2014).
41. Jessani, N., Liu, Y. S., Humphrey, M. & Cravatt, B. F. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl Acad. Sci. USA 99, 10335-10340 (2002).
42. Kidd, D., Liu, Y. S. & Cravatt, B. F. Profiling serine hydrolase activities in complex proteomes. Biochemistry 40, 4005-4015 (2001).
43. Li, J. et al. Simultaneous structure-activity studies and arming of natural products by C-H amination reveal cellular targets of eupalmerin acetate. Nat. Chem. 5, 510-517 (2013).
44. Luo, M. L. et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 66, 11690-11699 (2006).
45. Feldman, A. S., Banyard, J., Wu, C. L., McDougal, W. S. & Zetter, B. R. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin. Cancer Res. 15, 1024-1031 (2009).
46. Maclean, K. N. et al. Cystathionine protects against endoplasmic reticulum stress-induced lipid accumulation, tissue injury, and apoptotic cell death. J. Biol. Chem. 287, 31994-32005 (2012).
47. Dong, T. et al. Ainsliadimer A selectively inhibits IKK alpha/beta by covalently binding a conserved cysteine. Nat. Commun. 6, 6522 (2015).
48. Cox, J. et al. Accurate Proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteomics 13, 2513-2526 (2014).
49. DuBois, R. N. et al. The nuclear eicosanoid receptor, PPAR gamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19, 49-53 (1998).
50. Yang, Q. et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436, 356-362 (2005).
51. Zaytseva, Y. Y., Wallis, N. K., Southard, R. C. & Kilgore, M. W. The PPAR gamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via Both PPAR gamma-dependent and -independent mechanisms. Anticancer Res. 31, 813-823 (2011).
52. Kitz, R. & Wilson, I. B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 237, 3245-324 (1962).
53. Itoh, T. et al. Structural basis for the activation of PPAR gamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 15, 924-931 (2008).
54. Hughes, T. S. et al. An alternate binding site for PPAR gamma ligands. Nat. Commun. 5 Article number: 3571 (2014).
55. Isaac, M., Latour, J. M. & Seneque, O. Nucleophilic reactivity of Zinc-bound thiolates: subtle interplay between coordination set and conformational flexibility. Chem. Sci. 3, 3409-3420 (2012).
56. Lebrun, V. et al. Efficient oxidation and destabilization of Zn(Cys)(4) zinc fingers by singlet oxygen. Angew. Chem. Int. Ed. 53, 9365-9368 (2014).
57. Rice, W. G. et al. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of aids. Science 270, 1194-1197 (1995).
58. Spiegelman, B. M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514 (1998).
59. Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome proliferator-activated receptor gamma(Ppar-gamma). J. Biol. Chem. 270, 12953-12956 (1995).
60. Ahmadian, M. et al. PPAR gamma signaling and metabolism: the good, the bad and the future. Nat. Med. 19, 557-566 (2013).